Interferon alpha-2a biosimilar - Rhein Minapharm Biogenetics

Drug Profile

Interferon alpha-2a biosimilar - Rhein Minapharm Biogenetics

Alternative Names: Hansenula-derived interferon alpha-2a; IFN-alpha-2a biosimilar - Rhein Minapharm Biogenetics; Interferon alfa-2a biosimilar - Rhein Minapharm Biogenetics; Reiferon

Latest Information Update: 21 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rhein Minapharm Biogenetics
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 31 Dec 2005 Launched for Hepatitis C in Egypt (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top